Physician profile
Ryan Santin
NPI 1649698523
$2,036.06
in general payments reported to CMS, 2019-2025
25 companies · $1,270 in 2025
The $1,270 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $115 · 2024: $651 · 2025: $1,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,925 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,924.57 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $541.95 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $277.82 | 2023-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $153.22 | 2025 | Cobenfy, Eliquis, Camzyos |
| Otsuka America Pharmaceutical, INC. | $128.59 | 2023-2025 | Rexulti |
| Alkermes, INC. | $128.34 | 2023-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $116.25 | 2024-2025 | Invega Sustenna, Spravato |
| Vertex Pharmaceuticals Incorporated | $78.88 | 2025 | |
| Supernus Pharmaceuticals, INC. | $78.61 | 2024-2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.13 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $53.87 | 2023-2025 | Auvelity |
| Lundbeck LLC | $48.66 | 2023-2025 | Rexulti |
| Abbvie INC. | $45.33 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $34.88 | 2024-2025 | Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.44 | 2024 | Xifaxan |
| Exact Sciences Corporation | $33.24 | 2024 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $31.36 | 2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $30.84 | 2024-2025 | Mounjaro |
| Idorsia Pharmaceuticals US INC | $28.26 | 2023-2024 | Quviviq |
| Amgen INC. | $25.80 | 2024 | Tavneos |
| Abbott Laboratories | $24.93 | 2025 | Proclaim |
| Mylan Specialty L.P. | $20.30 | 2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $16.98 | 2024 | |
| Indivior INC. | $14.16 | 2024 | Perseris |
| Dexcom, INC. | $13.86 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.36 | 2024 | Jardiance, Synjardy, Tradjenta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Santin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.